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RepoRt
In children with sickle cell disease (SCD), primary and secondary 
prevention of strokes require indefinite regular blood transfusion 
therapy. The risks associated with repeated transfusions include 
alloimmunization and increased donor exposure. The Charles 
Drew Program is a directed blood donor program designed to 
lower donor exposure, decreasing the associated complications 
of transfusion; however, no evidence exists demonstrating the 
magnitude of the benefit to the recipient. Further, the use of 
extended red blood cell (RBC) antigen matching for C, E, and 
K has been well documented in a clinical trial setting but not 
extensively evaluated in a standard care setting. The goal of this 
study is to assess the effectiveness in reducing alloimmunization 
when matching for C, E, and K and the magnitude of the decrease 
in donor exposure in a directed blood donor program. The rate 
of alloimmunization and reduction of donor exposure were 
determined during the course of 1 year in a cohort of children 
with SCD who received regular directed donor blood transfusions. 
A total of 24 recipients were in the program, 16 females and 8 
males, 4 to 20 years of age. During 2008, alloimmunization 
was 0 percent and donor exposure was reduced by 20 percent, 
compared with usual care.  Extended RBC antigen matching has 
the same benefit as in a clinical trial setting for patients with 
SCD receiving blood transfusion therapy. Despite significant 
effort, we only achieved a modest decrease in donor exposure and 
cannot determine the immediate benefit of a directed blood donor 
program. Immunohematology 2012;28:7–12.
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Sickle cell disease (SCD) affects between 72,000 and 
98,000 people in the United States.1 Approximately 1 in 2600 
newborns and 1 in 400 African American newborns are born 
with SCD.1 Among children with sickle cell anemia (SCD-SS), 
strokes are one of the most devastating complications.2 By 14 
years of age, approximately 11 percent of children with SCD-
SS who are unscreened and untreated with prophylactic blood 
transfusion therapy will have an overt stroke, and 37.1 percent 
will have a silent cerebral infarct.3 Adams et al.4 demonstrated 
the relevance of transcranial Doppler (TCD) measurements 
for the primary prevention of overt strokes. Elevated TCD 
measurements are indicative of increased stroke risk; such 
testing should be used for early detection and initiation of 
treatment. The progression of neurologic complications 
typically results in regular blood transfusion therapy, proven 
to be effective in the primary and secondary prevention of 
overt strokes.5,6 In many large metropolitan areas or large 
referral centers, at least 20 or as many as 70 children with 
SCD receive regular blood transfusion therapy. Although red 
blood cell (RBC) transfusion therapy reduces the occurrence 
of strokes, it increases the risks of alloimmunization owing to 
repeated exposure to multiple blood donors. The persistent risk 
of alloimmunization for this susceptible population has been 
readily acknowledged, which has resulted in recommendations 
that individuals with SCD requiring regular blood transfusion 
therapy receive blood matched not only for ABO and D, but also 
for C, E, and K.7–13 However, College of American Pathologists 
surveys for RBC transfusion in patients with SCD in the United 
States show that transfusions are not generally matched for C, 
E, and K.14 Despite the common perception of the benefit of 
the strategy of extended RBC antigen matching for children 
with SCD who receive regular blood transfusion therapy, no 
randomized controlled trial has shown a direct benefit, and 
the relative merits of this strategy remain controversial.10
Blood banking centers that have minority recruitment 
programs have improved access to matched blood units.15–17 
Within the St. Louis metropolitan area, the Charles Drew 
Program has been implemented to initially educate African 
Americans about the importance of blood donation and 
subsequently to increase African American blood donor activity 
and retention.2 The additional objectives of the program are to 
(1) provide phenotypically matched (C, E, and K), hemoglobin 
S (HbS)-negative, leukocyte-reduced RBCs to all pediatric 
patients with SCD-SS who require regular blood transfusion 
therapy for primary or secondary prevention of overt strokes; 
(2) to ensure that donated blood units are fresh with the goal of 
limiting the interval from collection to transfusion to a period 
of 5 days; and (3) to limit the number of donors to which 
each patient is exposed. The Charles Drew Program has been 
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successful in increasing the rate of African American donors 
in the St. Louis metropolitan area. However, the primary 
donor pool for individuals with SCD who receive regular blood 
transfusion therapy is predominantly non African American.17 
This is a challenging disparity in blood donation practices 
among ethnic groups, with African American blood donors 
making less than 7 percent of donations in the United States, 
merely half of their proportion of the population, which is 13 
percent.17 Before the inception of the Charles Drew Program in 
the St. Louis metropolitan area, 3 percent of the units collected 
were from African Americans and now approximately 5 
percent are from African Americans.2 The annual total 
number of donated blood units increased from fewer than 
4000 units to an average of more than 12,000 units among 
African American blood donors.
Despite the success of the Charles Drew Program in 
effectively raising African American blood donor rates, the 
program does not have any evidence of the direct benefit of 
matched donors to the target patient population, namely 
children with SCD receiving ongoing blood transfusion 
therapy. Specifically, there is no evidence for a decrease in 
the rate of alloimmunization and no evidence that there is a 
decrease in the donor exposure rate, the two major objectives 
of the program. However, in 2008, a concerted effort was made 
by the leadership of both the local and national American Red 
Cross (ARC) in collaboration with the Pediatric Sickle Cell 
Disease Team at St. Louis Children’s Hospital to decrease the 
rate of donor exposure. The objectives of this study were to 
(1) determine the rate of alloimmunization in a directed blood 
donor program and (2) determine the rate of reduction of donor 
exposure for recipients of directed blood donor donations 
during the course of 2008.
Materials and Methods
This is a cohort study of all children who received blood 
donations from directed donors of the Charles Drew Program 
in 2008. This study was approved by the Institutional Review 
Board of the Human Research Protection Office at Washington 
University School of Medicine in St. Louis, Missouri, an affiliate 
of St. Louis Children’s Hospital. The Charles Drew Program is 
a directed blood donor program that serves patients with SCD 
at St. Louis Children’s Hospital located in St. Louis, Missouri.2 
Charles Drew Program donors are unique to the SCD population 
because they volunteer to donate solely for this program and 
for a single patient in the program. Predominantly, but not 
exclusively, African American donors are recruited from blood 
drives that are at least 40 percent African American using the 
standard recruitment and communication guidelines of the 
Charles Drew Program.2
Formative research in the form of focus groups was 
conducted with African American adults to guide efforts 
to recruit and retain program participants. The focus group 
discussion guides were designed around key constructs 
from the Health Belief Model18—namely, perceived benefits 
and barriers to blood donation. Based on this research, the 
recruitment and retention of Charles Drew Program donors 
consists at present of intensive educational outreach that 
includes information about SCD and the importance, logistics, 
and safety of blood donation; testimonials from patients with 
SCD; one on one discussion with donors and volunteers at 
blood drives; and recruitment tables at the conclusion of 
church services. Among other findings, the research indicated 
that appealing to altruistic motives on the part of blood donors 
could lead them to decide to participate in the program.19
There is at least one dedicated recruiter at the ARC 
committed to recruiting Charles Drew Program donors. 
Recruited blood donors are asked if they would agree to have 
their blood samples tested for compatibility with a patient 
in the Charles Drew Program. All RBC transfusions are 
leukocyte reduced. Additionally, all of the units transfused are 
phenotypically matched for C, E, and K in addition to ABO and 
D as supplied by the ARC, Missouri-Illinois Blood Services 
Region. After phenotyping, if donors are found to be a match 
for a particular patient, they are asked if they would agree 
to donate solely for a single patient with SCD. Charles Drew 
Program donors are asked to commit to donating blood two 
to three times per year, within 7 to 10 days of their matched 
patient’s scheduled transfusion date, for a period of 2 years. 
Retention strategies include reminder telephone calls near the 
recipient’s scheduled transfusion and an annual luncheon for 
the Charles Drew Program donors, sponsored by the ARC, to 
acknowledge the donors and their direct impact on the SCD 
community.
Statistical Analyses
Descriptive statistics were used to illustrate the age and 
sex of the recipients. The number of new clinically relevant 
alloantibodies divided by the total number of transfusion units 
provided for the entire cohort during 12 months was calculated 
to determine the rate of minor RBC alloimmunization. We 
calculated the percent of reduction in donor exposure by 
subtracting the number of donors from the number of blood 
units transfused and then dividing the remaining number of 
blood units by the total number of blood units transfused. For 
example, the reduction in donor exposure for Patient 1 (Table 1) 
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was calculated using 39 blood units transfused (assumption of 
1 donor per unit) minus 34, the actual number of donors, with 
a subsequent 13 percent (5 of 39) reduction in donor exposure.
Results
Demographics
A total of 24 children in the Charles Drew Program from 
St. Louis Children’s Hospital received blood transfusions 
between January 1, 2008, and December 31, 2008. The 
recipient blood transfusion history at St. Louis Children’s 
Hospital ranged from 24 to 216 units transfused. The recipients 
were from 4 to 20 years of age. There were 16 females and 8 
males. Among the cohort, chronic transfusion therapy was 
initiated for 3 recipients because of pain while they were being 
transitioned to hydroxyurea, 3 recipients for silent stroke, and 
18 recipients for overt stroke. The average interval between 
transfusions among all 24 recipients was approximately 39 
days, ranging from 28 to 55 days. For all study recipients, 
the mean number of units used for blood transfusions during 
2008 was 24 units, ranging from 6 to 49 units. The average age 
of the blood units on transfusion date was 7.4 days. All Charles 
Drew Program recipients receive either manual or automated 
RBC exchange transfusions for secondary prevention of overt 
stroke.20 Before the conduction of this study, a total of 4 (17%) 
patients had preexisting clinically relevant alloantibodies: 
3 patients exhibited anti-K, 2 patients exhibited anti-C, and 
1 patient exhibited anti-E. The data indicated that these 
alloantibodies developed before the patients participated in the 
Charles Drew Program.
Rate of Alloimmunization
Among the cohort, the rate of alloimmunization was 0 
percent (0 clinically relevant alloantibodies formed after 580 
units of blood were transfused during the entire year). During 
those 12 months, no recipients formed clinically relevant 
alloantibodies.
Decreased Rate of Donor Exposure
All 24 recipients of the Charles Drew Program from St. 
Louis Children’s Hospital had a reduction in the rate of donor 
exposure when compared with the expected numbers of donor 
exposures in the absence of a directed blood donor program. 
As a direct result of the program, the average reduction in 
donor exposure was approximately 20 percent, ranging from 
0 percent to 40 percent per patient enrolled in the program 
(Table 1).
Discussion
Blood donor programs and studies have been established 
to improve the quality of blood donations and to educate 
African Americans about SCD.17,21 However, to date, no 
direct benefits to children with SCD have been evaluated. To 
our knowledge, this is the first program that addresses the 
feasibility of both decreasing donor exposure and reducing the 
rate of alloimmunization for children with SCD who receive 
blood transfusion therapy. The Charles Drew Program is a 
concerted effort by the Missouri-Illinois ARC and the Sickle 
Cell Disease Team at St. Louis Children’s Hospital. During 
a 1-year period, the program decreased donor exposure 
by an average of 20 percent. Further, the program’s rate of 
alloimmunization was 0 percent (0 antibodies per 580 units 
transfused) versus 1.8 percent per unit transfused (45 new 
C, E, and K alloantibodies in 2461 units of blood transfusion 
therapy), the expected alloimmunization rate without an 
Table 1. Difference between the potential number of donor 
exposures needed (based on the assumption of one donor per 
unit) and the actual number of donors exposed and the overall 
reduction of donor exposure
Hospital 




Reduction of donor 
exposure (%)
Patient 1 39 34 13
Patient 2 35 26 26
Patient 3 17 14 18
Patient 4 6 6 0
Patient 5 17 15 12
Patient 6 33 24 27
Patient 7 17 15 12
Patient 8 26 25 0
Patient 9 8 8 0
Patient 10 16 13 19
Patient 11 21 18 14
Patient 12 49 39 20
Patient 13 39 30 30
Patient 14 22 17 23
Patient 15 32 23 28
Patient 16 28 20 29
Patient 17 10 9 10
Patient 18 33 22 33
Patient 19 37 35 5
Patient 20 20 13 35
Patient 21 25 22 12
Patient 22 10 9 10
Patient 23 15 13 13
Patient 24 25 15 40
Total: 580 Total: 465 Average: 20
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extended RBC antigen-matching program.9 This difference 
is statistically significant with a probability value of 0.001 
(Table 2A).
Our results are similar to the results obtained in the 
Stroke Prevention Trial in Sickle Cell Anemia (STOP) clinical 
trial in which matching for C, E, and K resulted in a rate of 
alloimmunization of 0.21 percent (4 new RBC alloantibodies in 
1830 units of blood transfused).7 There was no demonstrable 
difference between efficacy (clinical trial setting) and 
effectiveness (standard care setting) when C, E, and K are 
matched (0% and 0.21% per unit transfused; p = 0.260; 
Table 2B). We found no distinct advantage with a directed 
donor program for children with SCD who receive regular 
blood transfusion therapy beyond what would be expected 
in a standard extended RBC antigen-matching program in a 
clinical trial setting7 and a single-center study.22
The immediate clinical benefit of the extended RBC 
matching program is the decrease in the rate of alloimmu-
nization for a group of children who require indefinite blood 
transfusion therapy. Without such blood transfusions, patients 
are at a significant risk for ongoing neurologic injury.6,23,24 
Furthermore; it is often a challenge to provide matched 
blood donations for children and adults who develop multiple 
alloantibodies. This challenge becomes acute and urgent in the 
event of a single life-threatening incident, such as multiorgan 
failure or acute chest syndrome with respiratory failure.
One potential advantage of the directed donor program 
that includes the extended RBC antigen matching over just an 
extended RBC matching program alone is a decrease in donor 
exposure. Significantly limiting donor exposure will decrease 
the likelihood of graft rejection in the event of hematopoietic 
stem cell transplant (HSCT), the only proven cure for SCD and 
definitive treatment for strokes in this patient population.4 The 
rate of graft failure or rejection is strongly related to the number 
of donor exposures from transfusions.7,25–30 Thus, minimizing 
exposure to multiple blood donors becomes increasingly 
critical as HSCT becomes a viable option for the cure of SCD.
The potential advantage of decreasing donor exposure 
in children with SCD is theoretical. We cannot determine 
whether an annual 20 percent reduction in donor exposure is 
sufficient to decrease the rate of graft rejection for the small 
group of children who elect to receive HSCT. None of our 
patients in the cohort have subsequently undergone an HSCT. 
As this is only the first year of a unified effort to decrease donor 
exposure, we are optimistic that we can improve and sustain 
this effort. Ultimately the added effort of blood donor services 
coordinated with the hematology service must be balanced 
against the perceived but unproven advantage of decreased 
blood donor exposure for the entire SCD pediatric population.
In the current cohort study, no individuals developed 
alloantibodies specific to the RBC antigens to which they 
were matched. However, as in the STOP Trial, it is possible for 
individuals to develop alloantibodies regardless of matching. 
We have no definitive explanation as to why these alloantibodies 
form, but several potential explanations exist. Participants 
of directed blood donor programs may develop relevant 
alloantibodies if they were transfused outside of the primary 
hospital where their transfusions are normally received. 
Also C, E, or K antibodies can become undetectable and may 
later show up as a response to another immune stimulus. 
Additionally, technical errors by the person performing RBC 
phenotypes may occur, resulting in inaccurate interpretations 
and errors in transcription of the results. Further, weakly 
expressed antigens may render falsely negative phenotype 
results, a future component of antibody production.
In addition to the clinical benefits shown by this research, 
our study also provides preliminary evidence of the success 
of the Charles Drew Program in recruiting and retaining 
participants in a directed blood donor program. Although 
our study did not directly evaluate the success of the outreach 
Table 2A. Reduction in the rate of alloimmunization in extended 
RBC antigen-matching programs compared with historical control 
patients
Historical 
control STOP Trial p value
Number of clinically relevant 
antibodies developed (C, E, and K)
45 4
Number of total blood units 
transfused
2461 1830





Number of clinically relevant 
antibodies developed (C, E, and K)
45 0
Number of total blood units 
transfused
2461 580
Rate of alloimmunization 1.8 0.00 0.001
Table 2B. Reduction in the rate of alloimmunization in an extended 
RBC antigen-matching program with directed blood donations 
compared with extended RBC antigen matching alone
Charles Drew 
Program STOP Trial p value
Number of clinically relevant 
antibodies developed (C, E, and K)
0 4
Number of total blood units 
transfused
580 1830
Rate of alloimmunization 0.00 0.21 0.260
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program, specifically partnering with community churches, 
and informed by Health Belief Model constructs, the clinical 
results indicate that the programmatic and strategic decisions 
were successful and warrant additional study.
We have provided evidence that the benefit of extended 
RBC antigen matching is the same as in a clinical trial setting. 
However, for our second objective, we only achieved a modest 
decrease in donor exposure, despite significant effort by the 
ARC and the hematology services to decrease donor exposure. 
Further long-term evaluation of directed blood donor programs 
that target the reduction of donor exposure is warranted before 
this strategy is adopted by other hematology services and 
blood banks.
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